Clinical effects of Xingxiao Pill in the treatment of cancer

Dongfang Hospital, Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1) Patients will be diagnosed as malignant tumors with cytological or histopathological diagnosis , including respiratory tract tumors, gastrointestinal tumors and reproductive system tumors;
•2) Patients who have received chemotherapy in the past 1 month;
•3) Aged >= 18 years;
•4) Eastern Cooperative Oncology Group (ECOG) score <= 2 and estimated survival time > 1 month;
•5) Have certain reading ability;
•6) Voluntarily agree to participate in this study and sign the informed consent.

•1) Hyperthermia occurs within two weeks with a body temperature of more than 38 degrees C, or there is obvious active infection;
•2) Significant cardiovascular abnormalities (e.g., myocardial infarction, superior vena cava syndrome, grade 2 or above heart disease or uncontrolled hypertension before enrollment (systolic blood pressure over 160 mmHg or diastolic blood pressure over 100mmHg);
•3) Serum bilirubin is 1.5 times higher than the upper limit of the reference range of normal value;
•4) The serum myoliver is 1.5 times higher than the upper limit of the reference range of normal value or myoliver clearance rate < 50 ml/min;
•5) ALT or AST > in the absence of liver metastasis; 2.5 times the upper limit of the normal value, or 5 times the upper limit of the reference range of ALT or AST in the case of liver metastasis;
•6) Pregnant or lactating women;
•7) Persons with mental illness or intellectual or language impairment;
•8) Patients who are known to be allergic to the components used in the study;
•9) Patients who are participating in other drug trials within the past month or so;

发起方

Dongfang Hospital, Beijing University of Chinese Medicine